Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115582 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von David O'Reilly und 41 weiteren Autor:innen. Beteiligte Einrichtung: Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland. Electronic address: Davidoreilly22@rcsi.ie. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, High-Throughput Nucleotide Sequencing, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Irish Cancer Society, Novartis AG, AstraZeneca PLC.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland. Electronic address: Davidoreilly22@rcsi.ie.
- Department of Pathology, Beaumont RCSI Cancer Centre, Dublin, Ireland.
- Trinity St James Cancer Institute, Dublin, Ireland.
- Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland.
- Department of Histopathology, Beaumont Hospital, Beaumont Road, Dublin 9, Ireland.
- Irish Lung Cancer Community, Ireland.
Förderung
- Irish Cancer Society
- Novartis AG
- AstraZeneca PLC
- Amgen Foundation Inc
Zitieren
APA
O'Reilly, D., O'Grady, A., Hayes, C., Piggott, L., Keane, R., Fitzpatrick, O. M., Conroy, M., Aretz, N. K., Synnott, D., Dillon, R., Dowling, G. P., Ryan, D. J., O'Brien, E., Morgan, R., Breathnach, O., Grogan, L., Morris, P., Greally, M., Teo, M. Y., …, & Naidoo, J. (2025). Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115582
Vancouver
O'Reilly D, O'Grady A, Hayes C, Piggott L, Keane R, Fitzpatrick OM, et al. Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115582
BibTeX
@article{OReilly2025,
author = {O'Reilly, David and O'Grady, Anthony and Hayes, Conor and Piggott, Laura and Keane, Ruaidhri and Fitzpatrick, Orla M and Conroy, Michael and Aretz, Nicholas Kruseman and Synnott, David and Dillon, Rachel and Dowling, Gavin P and Ryan, Daniel J and O'Brien, Emmet and Morgan, Ross and Breathnach, Oscar and Grogan, Liam and Morris, Patrick and Greally, Megan and Teo, Minh Yuen and Murphy, Adrian and Ryan, Gillian and Counihan, Ian and Ryan, Cliona and Barrett, Helen and O'Shea, Ann-Marie and Cuffe, Sinead and Korpanty, Grzegorz and Prior, Lisa and Barr, Martin P and Finn, Stephen and O'Brien, Cathal and McCarron, Sarah and Cummins, Rob and Toomey, Sinead and Dowling, Catríona M and Glavey, Siobhan and Hennessy, Bryan T and Sorensen, Jan and Bennett, Kathleen and Nadarajan, Parthiban and Doyle, Brendan and Naidoo, Jarushka},
title = {Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115582}
}
EUVIMED